The survival prediction of hospitalized patients with COVID-19: the role of chitotriosidase level in peripheral blood

Cover Page

Cite item

Full Text

Abstract

Aim. To assess the relationship between plasma chitotiosidase (CHIT) level and mortality in hospitalized patients with COVID-19.

Materials and methods. 347 hospitalized patients with COVID-19 were enrolled in our single-center cohort prospective observational study. On the first day of hospitalization the patients were assessed by the level of CHIT in the venosus blood to addition to default laboratory examinations. The primary endpoint was all-cause death. The survival after hospital discharge were assessed via phone calls on 90 and 180 days since inclusion to the study (NCT04752085).

Results. Our study included 347 patients. The first symptoms appeared in 7 days [5; 7] before hospitalization; 283 (84.3%) patients had less than 50% of the involvement of the lung tissue to the inflammation process (CT 0–2); 36 (10.4%) patients had died since the start of our investigation; 30 (83.3%) of them died during hospitalization, others -no later than 60 days; 68 (19%) people didn’t answer during phone call. The survivor's activity of the enzyme in the deceased was significantly lower in compare to deceased patients (90.5 [40.2; 178.0] nmol/h/mL vs 180.0 [77.2; 393.2] nmol/h/mL; p=0.001). Survivor of the patients with a higher level of the activity of the CHIT (more than 171 nmol/h/mL) was statically significantly lower.

Conclusion. Rising of the CHIT's activity more than 171 nmol/h/mL might be an early independent predictor of the bad prognosis of the patients, who were hospitalized with COVID-19 infection.

About the authors

Ekaterina S. Schelkanovtseva

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0001-9098-4098

аспирант каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Georgy O. Isaev

Sechenov First Moscow State Medical University (Sechenov University)

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-4871-8797

ординатор каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Olga Yu. Mironova

Sechenov First Moscow State Medical University (Sechenov University)

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-5820-1759

канд. мед. наук, проф. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Alexander A. Balakhonov

Sechenov First Moscow State Medical University (Sechenov University)

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-1166-9856

аспирант каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Alexey V. Skvortsov

Lomonosov Moscow State University

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0001-8743-5207

ординатор фак-та фундаментальной медицины

Russian Federation, Moscow

Ilya O. Nagornov

Bochkov Medical Genetic Research Center

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0001-9368-1594

врач – лабораторный генетик

Russian Federation, Moscow

Aleksandr Yu. Suvorov

Sechenov First Moscow State Medical University (Sechenov University)

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-2224-0019

канд. мед. наук, гл. статистик НЦМУ «Цифровой биодизайн и персонализированное здравоохранение»

Russian Federation, Moscow

Victor V. Fomin

Sechenov First Moscow State Medical University (Sechenov University)

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-2682-4417

чл.-кор. РАН, д-р мед. наук, проф., зав. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Alexandr S. Panferov

Sechenov First Moscow State Medical University (Sechenov University)

Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-4324-7615

канд. мед. наук, доц. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

References

  1. «Профилактика, диагностика и лечение новой коронавирусной инфекции 2019-nCoV». Временные методические рекомендации Министерства здравоохранения Российской Федерации. 2021; версия 12. Режим доступа: https://base.garant.ru/400738625/ Ссылка активна на 09.08.2022 [«Prevention, diagnosis and treatment of new coronavirus infection 2019-nCoV». Interim methodological recommendations of the Ministry of Health of the Russian Federation. 2021; version 12. Available at: https://base.garant.ru/400738625/ Accessed: 09.08.2022 (in Russian)].
  2. Gooday GW. Aggressive and defensive roles for chitinases. EXS. 1999;87:157-69. doi: 10.1007/978-3-0348-8757-1_11
  3. Lee CG, Da Silva CA, Cruz CSD, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Ann Rev Physiol. 2011;73:1. DOI:0.1146/ANNUREV-PHYSIOL-012110-142250
  4. Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol. 2012;5:1. doi: 10.2174/1875044301205010001
  5. Chang D, Sharma L, Cruz CSD. Chitotriosidase: a marker and modulator of lung disease. Eur Respir Rev. 2020;29:156. doi: 10.1183/16000617.0143-2019
  6. Sharma L, Amick AK, Vasudevan S, et al. Regulation and role of chitotriosidase during lung infection with Klebsiella pneumoniae. J Immunol. 2018;201(2):615-26. doi: 10.4049/JIMMUNOL.1701782/-/DCSUPPLEMENTAL
  7. Bennett D, Cameli P, Lanzarone N, et al. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020;21(1):1-12. doi: 10.1186/s12931-019-1263-z
  8. Mazur M, Zielińska A, Grzybowski M, et al. Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases. Int J Mol Sci. 2021;22(13):6966. doi: 10.3390/IJMS22136966
  9. Cakır G, Gumus S, Ucar E, et al. Serum chitotriosidase activity in pulmonary tuberculosis: response to treatment and correlations with clinical parameters. Ann Lab Med. 2012;32(3):184-9. doi: 10.3343/ALM.2012.32.3.184
  10. Kernan K, Carcillo J. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401-9. doi: 10.1093/INTIMM/DXX031
  11. Feld J, Tremblay D, Thibaud S, et al. Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2020;42(6):773-9. doi: 10.1111/IJLH.13309
  12. Violi F, Cangemi R, Romiti GF, et al. Is Albumin Predictor of Mortality in COVID-19? Antioxid Redox Signal. 2021;35(2):139-42. doi: 10.1089/ARS.2020.8142

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The Kaplan–Meyer curve shows the survival rate of patients with coronavirus infection with a chitotriozidase level above the 171 nmol/ml/h threshold.

Download (88KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies